[A26-73] Teplizumab (type 1 diabetes mellitus, stage 2, >= 8 years) – Addendum to Project A26-11
Last updated 06.08.2026
Project no.:
A26-73
Commission:
Commission awarded on 23.06.2026 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Indication:
Adult and paediatric patients 8 years of age and older with stage 2 type 1 diabetes mellitus, to delay the onset of stage 3
Result of dossier assessment:
- Unchanged after addendum: For patients with a family history: added benefit not proven (based on the results of the relevant study)
- Unchanged after addendum: For patients without a family history: added benefit not proven (no relevant study)
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI:
https://doi.org/10.60584/A26-73
| Project no. | Title | Status |
|---|---|---|
| A26-11 | Teplizumab (type 1 diabetes mellitus, >= 8 years) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
06-08-2026 A G-BA decision was published.
G-BA documents on this decision